FDA objects to AstraZeneca sales rep touting off-label Seroquel
This article was originally published in Scrip
Executive Summary
In a letter toAstraZeneca, the USFDA's division of drug marketing, advertising and communication stated that it has become aware of an incident whereby a sales rep from the company suggested an unapproved use for Seroquel (quetiapine fumarate).